The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients
The study examines efgartigimod and intravenous immunoglobulin (IVIg) in elderly patients with generalized myasthenia gravis (GMG), focusing on changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, pyridostigmine dosage, and minimal symptom expression (MSE) over an 8-week period. Among 74 enrolled patients, efgartigimod showed greater reduction in MG-ADL scores compared to IVIg at weeks 4 and 8, with no serious adverse events, suggesting its superior efficacy and safety in elderly Chinese patients with acetylcholine receptor antibody-positive (AChR-Ab(+)) GMG.
Authors
- Yufei Deng (ORCID: https://orcid.org/0009-0009-6953-6771)
- Xiang Yan (ORCID: https://orcid.org/0000-0002-3683-474X)
- Qilong Jiang (ORCID: https://orcid.org/0000-0001-9387-1259)
- Xiang Li (ORCID: https://orcid.org/0000-0002-5147-8368)
- Chaoyue Zhang
- Haocheng Luo
- Xiaojun Yang (ORCID: https://orcid.org/0000-0001-9833-6415)
- Shuangshuang Wang (ORCID: https://orcid.org/0000-0003-1634-5399)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
Publication Details
- Journal
- Clinical Immunology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.clim.2025.110457
- Citations
- 5
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 6.95